BCMA is selectively induced during plasma cell differentiation and is nearly absent on naive and memory B cells (Avery et al., 2003; Chiu et al., 2007). The interaction between BCMA and its ligand BAFF and APRIL is involved for the maintenance of long-lived plasma cells (O'Connor et al., 2004; Peperzak et al., 2013). Multiple BCMA-targeted therapies of B-cell derived malignancies are underdevelopment, including BCMA-targeting chimeric antigen receptor T (CAR-T) and GlaxoSmithKline's GSK2857916.
Selective interaction between BAFF/APRIL and their receptors. Note BCMA can interact with both BAFF and APRIL (Bolkun et al., 2016). The affinity of APRIL-BCMA interaction, however, is much higher than that of BAFF-BCMA binding (Bossen and Schneider, 2006).
ACROBiosystems provides a comprehensive panel of BCMA proteins, including the exclusive biotinylated BCMA (Cat. # BC7-H82F0) and the monomeric BCMA (Cat. # BCA-H522y).
Immobilized Human BAFF, Fc Tag (Catalog # BAF-H4268) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, Fc Tag (Cat. # BC7-H82F0) with a linear range of 0.12-1.95 ng/mL.
The purity of Human BCMA, His Tag (Cat. # BCA-H522y) is greater than 93% as determined by SEC-HPLC.
Immobilized Human BCMA, His Tag (Cat. # BCA-H522y) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BAFF (Cat. # BAF-H82Q2) with a linear range of 0.24-3.9 ng/mL.
BCMA和单体BCMA蛋白分子列表
咨询电话：400-682-2521
电子邮箱：order.cn@acrobiosystems.com